Stock listing

gettex:NPAU BetterLife Pharma Inc. Aktie

German listing (gettex) of BetterLife Pharma Inc. · home listing CSE:BETR

Follow BetterLife Pharma Inc. into a list and get an email when it puts out news.

Home listing price · CSE:BETR

$0.185 CAD -0.020 (-9.8%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, CSE:BETR

Past year +270.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.185 – $0.200 CADNov 20, 2026
Volume
105,700 sharesNov 20, 2026
Market cap
$120.5M CADAt the close on Nov 20, 2026 · price × 651.3M shares outstanding
52-week range
$0.040 – $0.460 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$116,452 CADMedian day 256,309 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
BetterLife Pharma Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
CSE:BETR · Home$0.185 CAD-0.020 (-9.8%)105,700$0.190$0.200$0.185$0.205Close on Nov 20, 2026
OTC:BETRF$0.139 USD-0.002 (-1.3%)2,500$0.133$0.139$0.133$0.141Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · CSE:BETR · CAD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.185-0.020-9.8%$0.190$0.200$0.185105,700
$0.205-0.005-2.4%$0.185$0.220$0.180219,507
$0.210+0.010+5.0%$0.215$0.225$0.200609,125
$0.2000.0000.0%$0.200$0.220$0.185107,000
$0.200-0.015-7.0%$0.200$0.200$0.200550
$0.215+0.010+4.9%$0.200$0.215$0.20031,620
$0.205+0.015+7.9%$0.195$0.205$0.195268,500
$0.190-0.015-7.3%$0.200$0.215$0.1802,098,071
$0.205-0.020-8.9%$0.220$0.225$0.205161,500
$0.225+0.005+2.3%$0.230$0.230$0.210341,300
$0.220-0.010-4.3%$0.220$0.220$0.215118,666
$0.230+0.005+2.2%$0.225$0.230$0.215128,554
$0.225-0.015-6.2%$0.240$0.240$0.220622,500
$0.240-0.010-4.0%$0.250$0.250$0.240142,106
$0.2500.0000.0%$0.260$0.260$0.245750,847
$0.250+0.010+4.2%$0.245$0.260$0.245144,000
$0.240+0.015+6.7%$0.235$0.250$0.235116,021
$0.2250.0000.0%$0.230$0.230$0.22016,600
$0.2250.0000.0%$0.230$0.235$0.225248,100
$0.225-0.020-8.2%$0.240$0.240$0.225345,435
$0.245-0.005-2.0%$0.250$0.260$0.230501,610
$0.250+0.050+25.0%$0.210$0.285$0.2102,032,641
$0.200-0.010-4.8%$0.210$0.215$0.200144,800
$0.2100.0000.0%$0.210$0.225$0.210116,326
$0.210-0.015-6.7%$0.230$0.230$0.210467,301
$0.225+0.005+2.3%$0.225$0.230$0.220132,057
$0.220-0.025-10.2%$0.250$0.250$0.220456,300
$0.245-0.010-3.9%$0.260$0.260$0.245300,607
$0.255-0.015-5.6%$0.280$0.280$0.255314,343
$0.270+0.010+3.8%$0.260$0.270$0.250311,500
$0.260-0.005-1.9%$0.260$0.270$0.260129,967
$0.265-0.025-8.6%$0.295$0.295$0.265269,089
$0.290+0.025+9.4%$0.290$0.290$0.27030,701
$0.265-0.005-1.9%$0.270$0.285$0.265372,951
$0.270-0.075-21.7%$0.315$0.320$0.270921,958
$0.345+0.060+21.1%$0.300$0.345$0.29073,010
$0.285-0.025-8.1%$0.315$0.315$0.285283,489
$0.310-0.025-7.5%$0.330$0.330$0.305319,050
$0.335-0.015-4.3%$0.350$0.355$0.330198,701
$0.350+0.015+4.5%$0.335$0.350$0.335184,428
$0.335+0.015+4.7%$0.335$0.345$0.330181,700
$0.320+0.015+4.9%$0.320$0.330$0.305209,113
$0.305-0.025-7.6%$0.335$0.350$0.3001,535,561
$0.330-0.030-8.3%$0.355$0.360$0.330248,618
$0.3600.0000.0%$0.350$0.390$0.340861,522
$0.360-0.020-5.3%$0.390$0.390$0.350505,800
$0.380-0.020-5.0%$0.400$0.400$0.360392,698
$0.400+0.060+17.6%$0.340$0.400$0.3401,124,392
$0.340+0.035+11.5%$0.315$0.340$0.315184,786
$0.305+0.005+1.7%$0.300$0.310$0.300264,000
$0.300-0.005-1.6%$0.305$0.305$0.30044,015
$0.305+0.005+1.7%$0.305$0.305$0.30031,533
$0.3000.0000.0%$0.305$0.305$0.300615,167
$0.300+0.015+5.3%$0.285$0.310$0.280892,540
$0.285-0.005-1.7%$0.295$0.295$0.280195,000
$0.2900.0000.0%$0.310$0.310$0.280116,316
$0.290-0.025-7.9%$0.325$0.325$0.290854,369
$0.315+0.005+1.6%$0.345$0.345$0.290590,644
$0.310-0.060-16.2%$0.350$0.355$0.3002,554,040
$0.370-0.010-2.6%$0.375$0.380$0.35039,195
$0.380+0.060+18.8%$0.320$0.380$0.300441,701
$0.320-0.005-1.5%$0.320$0.320$0.295238,893
$0.325+0.010+3.2%$0.320$0.330$0.300266,880
$0.315-0.035-10.0%$0.315$0.340$0.310169,019
Ticker
gettex:NPAU
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
gettex
Currency
EUR

What changed lately

Latest news

All BetterLife Pharma Inc. news

BetterLife Pharma Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
30 in the last 12 months · 86 in all · newest Nov 20, 2026 · oldest 2017
Decks
5 decks · latest July 2026

Where BetterLife Pharma Inc. is listed

ListingExchangeCountryCurrency
CSE:BETR · Home listingCSECanadaCAD
OTC:BETRFOTCUnited StatesUSD
Cboe Canada:BETRCboe CanadaCanadaCAD
Frankfurt:NPAUFrankfurtGermanyEUR
LS Exchange:A2P7XNLS ExchangeGermanyEUR
Lang & Schwarz:A2P7XNLang & SchwarzGermanyEUR
gettex:NPAU · This pagegettexGermanyEUR
Stuttgart:NPAUStuttgartGermanyEUR
Munich:NPAUMunichGermanyEUR

Valuation

Statements: 4 quarters to Jul 31, 2026 · price Nov 20, 2026

Enterprise value
$119.6M CAD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P/TSX Composite
1.14

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
BetterLife Pharma Inc. · CSE:BETRUS$84.02MUS$83.36Mn/an/an/an/an/an/a1.14
Bioceltix SA · GPW:BCXUS$86.39MUS$72.44Mn/an/an/a5.6×n/a0.0×n/a
Perspective Therapeutics, Inc. · AMEX:CATXUS$86.05M−US$114.1Mn/a−570×n/a0.3×n/a0.0×1.47
Pharmosa Biopharm Inc. · TPEX:6875US$86.02MUS$62.26Mn/a38.5×n/a2.1×−658.1%0.1×n/a
Formosa Pharmaceuticals, Inc. · TWSE:6838US$85.42MUS$48.51Mn/a30.4×n/a2.0×−361.4%0.0×n/a
Anixa Biosciences, Inc. · NASDAQ:ANIXUS$84.82MUS$70.96Mn/an/an/a5.9×n/a0.0×1.45
Genome & Co. · KRX:314130US$84.75MUS$36.98Mn/a2.0×n/a1.6×−169.1%0.0×n/a
Shine-On Biomedical Co., Ltd. · TPEX:6926US$83.54MUS$59.01Mn/a64.8×n/a3.5×−367.6%0.0×n/a
Rallybio Corporation · NASDAQ:RLYBUS$83.29M−US$7.40M3.1×−17.1×n/a0.9×n/a0.0×0.58
TuHURA Biosciences, Inc. · NASDAQ:HURAUS$82.20MUS$89.50Mn/an/an/a4.3×n/a0.5×2.81
3D Medicines, Inc. · HKEX:1244US$81.88MUS$48.38Mn/a0.9×n/a1.0×−49.9%0.3×n/a
Median of the othersUS$84.79MUS$53.76M3.1×2.0×2.1×−361.4%0.0×1.46

Team and board

Officers

OfficerRole
Ahmad DoroudianChief Executive Officer & Director
Douglas DrysdaleExecutive Chairman
Mahan ChehrenamaChief Medical Officer
Sheila LeitzingerHead of Clinical Operations

Board

DirectorRole
Douglas DrysdaleExecutive Chairman
Ahmad DoroudianChief Executive Officer & Director
Charles DuncanDirector
Henry ChowMember of the Board of Directors
John W. LaRoccaDirector

Events

QuarterResultsShare move
Q1 2024May 30, 2023 · After close−11.1%
Q3 2023Dec 22, 2022 · After close+6.1%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (July 2026)Investor deck18 slidesJuly 2026
Investor Presentation (January 2023)Investor deck15 slidesJan 13, 2023
Investor Presentation (August 2022)Investor deck15 slidesAugust 2022
Investor Presentation (December 2021)Investor deck23 slidesDecember 2021
Investor Presentation (May 2021)Investor deck27 slidesMay 26, 2021

Open Decks

Financings

RaiseDateIn US dollars
Public offering of common shares and pre-funded warrants
Closed: US$100M raised · C$0.25 a share · Bloom Burton Securities Inc. +1
Dealers: Bloom Burton Securities Inc. (lead), Haywood Securities Inc.
Buyers: Deep Track Capital (led the financing); Coastlands Capital (significant co-investment); Marshall Wace (significant co-investment); RA Capital Management (significant co-investment); Perceptive Advisors (significant co-investment); Adage Capital Management (participation); Affinity Asset Advisors (participation); Kalehua Capital (participation); Sphera Fund Management (participation); Squadron Capital Management (participation); Stonepine Capital Management (participation); Woodline Partners LP (participation)
Use of proceeds: Phase 1A, Phase 1B and Phase 2 clinical trials of BETR-001 in cluster headache and migraine, plus working capital and general corporate purposes
Sep 17, 2026
Convertible debenture
Closed: C$2M raised · C$0.06 · 1 warrant at C$0.1 for 36 months
Insiders: A director and insider of the Company subscribed for $2,000,000 of the Debenture; conversion subject to a 19.9% ownership cap absent shareholder approval
Use of proceeds: Complete remaining IND-enabling activities for BETR-001 and general working capital
Jun 22, 2026US$1.41M
Warrant exercise of common shares on exercise of share purchase warrants
Closed: C$25,000 raised
May 6, 2025US$18,138

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in CAD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue000000000
Research and development85.7K424.3K570.9K2.68M5.42M284.7K63.8K364.8K86.7K
Selling, general and administrative1.72M4.30M2.64M6.56M4.53M7.56M7.74M5.13M1.04M
Operating income-1.81M-5.00M-3.24M-9.46M-9.97M-7.95M-9.20M-6.46M-1.16M
Depreciation and amortization0018.4K18.4K18.4K2.92K1.14K30.8K30.8K
EBITDA-5.00M-3.24M-9.44M-9.95M-7.94M-9.20M-6.46M-1.13M
Interest expense231.9K165.1K45.5K11.5K51.8K7.05K48.0K4.86K00
Income before tax-1.51M-3.62M-2.90M-9.37M-12.0M-36.4M-19.6M-9.15M-149.5K
Income tax166.7K
Net income-1.50M-3.62M-2.90M-9.37M-12.2M-36.4M-19.6M-9.25M-149.5K
Earnings per share, basic-0.01-0.08-0.05-0.31-0.39-0.71-0.25-0.96-0.02
Earnings per share, diluted-0.03-0.03-0.10-0.16-1.34-1.30-1.03

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents12.6K8.18K37.4K8.31K173.5K154.7K3.28M74.8K79.6K
Receivables2.86K11.6K39.5K17.2K325.0K520.1K137.4K44.5K5.12K
Current assets219.9K225.0K324.7K74.7K1.14M1.33M3.48M217.4K183.5K129.8K
Property, plant and equipment18.4K36.9K542.7K5.31K
Total assets219.9K225.0K324.7K74.7K1.16M1.34M8.25M10.3M473.5K
Accounts payable3.95M4.50M4.98M5.44M3.34M4.50M-2.37K637.3K267.9K996.9K
Current liabilities6.68M7.54M7.35M7.15M4.14M5.85M960.1K5.40M527.6K1.61M
Long-term debt27.2K49.1K49.1K034.6K0
Total debt99.2K80.0K74.6K0
Total liabilities6.71M7.59M8.02M7.61M5.04M5.98M5.59M6.81M529.5K
Shareholders' equity-9.78M-7.36M-7.70M-7.53M-3.88M-4.61M2.66M3.50M-56.0K
Shares outstanding151.9M43.5M52.8M30.1M31.3M51.4M79.5M9.69M8.24M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-625.5K-2.02M-2.47M-1.50M-11.2M-7.16M-7.88M-4.71M-561.5K-359.4K
Capital spending00000-10.2K-542.7K0-542.7K-542.7K
Free cash flow-625.5K-2.02M-2.47M-1.50M-11.2M-7.18M-8.42M-4.71M-488.1K-902.2K
Cash from investing-71.5K-1.14M-844.4K-844.4K-844.4K
Cash from financing629.3K1.99M2.50M1.34M11.2M4.09M12.2M5.55M457.3K379.7K
Change in cash4.39K-29.2K29.1K-165.2K18.8K-3.13M3.21M-4.50K-67.7K40.8K

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerSep 29, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeSep 22, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerSep 15, 2026Current reportSEC
6-K · Report of a foreign issuerSep 11, 2026Current reportSEC
6-K · Report of a foreign issuerAug 24, 2026Current reportSEC
6-K · Report of a foreign issuerAug 4, 2026Current reportSEC
6-K · Report of a foreign issuerJun 26, 2026Current reportSEC
6-K · Report of a foreign issuerJun 25, 2026Current reportSEC
20-F · Annual reportJun 1, 2026Annual reportSEC
6-K · Report of a foreign issuerApr 13, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
6-K · Report of a foreign issuerSep 29, 2025Current reportSEC
6-K · Report of a foreign issuerJul 28, 2025Current reportSEC
6-K · Report of a foreign issuerJun 27, 2025Current reportSEC
6-K · Report of a foreign issuerJun 23, 2025Current reportSEC
20-F · Annual reportJun 2, 2025Annual reportSEC
6-K · Report of a foreign issuerMay 29, 2025Current reportSEC
6-K · Report of a foreign issuerMay 6, 2025Current reportSEC
6-K · Report of a foreign issuerApr 7, 2025Current reportSEC
6-K · Report of a foreign issuerDec 31, 2024Current reportSEC
6-K · Report of a foreign issuerDec 9, 2024Current reportSEC
6-K · Report of a foreign issuerOct 15, 2024Current reportSEC
6-K · Report of a foreign issuerSep 26, 2024Current reportSEC
6-K · Report of a foreign issuerAug 29, 2024Current reportSEC
6-K · Report of a foreign issuerAug 8, 2024Current reportSEC
6-K · Report of a foreign issuerJul 15, 2024Current reportSEC
6-K · Report of a foreign issuerJun 27, 2024Current reportSEC
6-K · Report of a foreign issuerJun 17, 2024Current reportSEC
20-F · Annual reportMay 30, 2024Annual reportSEC
6-K · Report of a foreign issuerMay 14, 2024Current reportSEC
6-K · Report of a foreign issuerMay 6, 2024Current reportSEC
6-K · Report of a foreign issuerApr 11, 2024Current reportSEC
6-K · Report of a foreign issuerApr 4, 2024Current reportSEC
6-K · Report of a foreign issuerMar 5, 2024Current reportSEC
6-K · Report of a foreign issuerJan 2, 2024Current reportSEC
6-K · Report of a foreign issuerDec 29, 2023Current reportSEC
6-K · Report of a foreign issuerDec 18, 2023Current reportSEC
6-K · Report of a foreign issuerNov 30, 2023Current reportSEC
6-K · Report of a foreign issuerSep 29, 2023Current reportSEC
6-K · Report of a foreign issuerSep 28, 2023Current reportSEC
6-K · Report of a foreign issuerSep 5, 2023Current reportSEC
6-K · Report of a foreign issuerJul 13, 2023Current reportSEC
6-K · Report of a foreign issuerJun 28, 2023Current reportSEC
6-K · Report of a foreign issuerJun 28, 2023Current reportSEC
6-K · Report of a foreign issuerJun 9, 2023Current reportSEC
20-F/A · Annual report, amendedJun 6, 2023Annual reportSEC
20-F · Annual reportMay 31, 2023Annual reportSEC
6-K · Report of a foreign issuerMay 10, 2023Current reportSEC
6-K · Report of a foreign issuerApr 25, 2023Current reportSEC
6-K · Report of a foreign issuerMar 14, 2023Current reportSEC
6-K · Report of a foreign issuerMar 8, 2023Current reportSEC
6-K · Report of a foreign issuerMar 7, 2023Current reportSEC
6-K · Report of a foreign issuerFeb 28, 2023Current reportSEC
6-K · Report of a foreign issuerJan 18, 2023Current reportSEC
6-K · Report of a foreign issuerDec 23, 2022Current reportSEC
6-K · Report of a foreign issuerDec 8, 2022Current reportSEC
6-K · Report of a foreign issuerNov 8, 2022Current reportSEC
6-K · Report of a foreign issuerSep 27, 2022Current reportSEC
6-K · Report of a foreign issuerJul 12, 2022Current reportSEC
6-K · Report of a foreign issuerJun 29, 2022Current reportSEC
20-F · Annual reportJun 6, 2022Annual reportSEC
NT 20-FMay 31, 2022Explanation requestSEC
6-K · Report of a foreign issuerApr 6, 2022Current reportSEC
6-K · Report of a foreign issuerMar 4, 2022Current reportSEC
6-K · Report of a foreign issuerJan 20, 2022Current reportSEC
6-K · Report of a foreign issuerDec 23, 2021Current reportSEC
6-K · Report of a foreign issuerDec 16, 2021Current reportSEC
6-K · Report of a foreign issuerDec 15, 2021Current reportSEC
6-K · Report of a foreign issuerDec 9, 2021Current reportSEC
6-K · Report of a foreign issuerNov 23, 2021Current reportSEC
6-K · Report of a foreign issuerNov 16, 2021Current reportSEC
6-K · Report of a foreign issuerOct 20, 2021Current reportSEC
6-K · Report of a foreign issuerSep 29, 2021Current reportSEC
6-K · Report of a foreign issuerSep 23, 2021Current reportSEC
6-K · Report of a foreign issuerSep 21, 2021Current reportSEC
6-K · Report of a foreign issuerAug 3, 2021Current reportSEC
6-K · Report of a foreign issuerJul 16, 2021Current reportSEC
6-K · Report of a foreign issuerJun 28, 2021Current reportSEC
6-K · Report of a foreign issuerJun 25, 2021Current reportSEC
20-F/A · Annual report, amendedJun 23, 2021Annual reportSEC
20-F/A · Annual report, amendedJun 8, 2021Annual reportSEC
6-K · Report of a foreign issuerJun 7, 2021Current reportSEC
6-K · Report of a foreign issuerJun 7, 2021Current reportSEC
20-F · Annual reportJun 1, 2021Annual reportSEC
6-K · Report of a foreign issuerMay 28, 2021Current reportSEC
6-K · Report of a foreign issuerMay 21, 2021Current reportSEC
6-K · Report of a foreign issuerMay 14, 2021Current reportSEC
6-K · Report of a foreign issuerMay 5, 2021Current reportSEC
6-K · Report of a foreign issuerApr 26, 2021Current reportSEC
6-K · Report of a foreign issuerApr 20, 2021Current reportSEC
6-K · Report of a foreign issuerApr 1, 2021Current reportSEC
6-K · Report of a foreign issuerMar 16, 2021Current reportSEC
6-K · Report of a foreign issuerMar 15, 2021Current reportSEC
6-K · Report of a foreign issuerMar 8, 2021Current reportSEC
6-K · Report of a foreign issuerFeb 2, 2021Current reportSEC
6-K · Report of a foreign issuerJan 19, 2021Current reportSEC
6-K · Report of a foreign issuerDec 30, 2020Current reportSEC
6-K · Report of a foreign issuerDec 29, 2020Current reportSEC
6-K · Report of a foreign issuerDec 22, 2020Current reportSEC
6-K · Report of a foreign issuerDec 8, 2020Current reportSEC
6-K · Report of a foreign issuerDec 2, 2020Current reportSEC
6-K · Report of a foreign issuerNov 23, 2020Current reportSEC
6-K · Report of a foreign issuerOct 20, 2020Current reportSEC
6-K · Report of a foreign issuerOct 9, 2020Current reportSEC
6-K · Report of a foreign issuerSep 28, 2020Current reportSEC
6-K · Report of a foreign issuerSep 9, 2020Current reportSEC
6-K/A · Report of a foreign issuer, amendedAug 17, 2020Current reportSEC
6-K · Report of a foreign issuerAug 11, 2020Current reportSEC
6-K · Report of a foreign issuerJul 31, 2020Current reportSEC
6-K · Report of a foreign issuerJun 29, 2020Current reportSEC
6-K · Report of a foreign issuerJun 29, 2020Current reportSEC
6-K · Report of a foreign issuerJun 15, 2020Current reportSEC
6-K · Report of a foreign issuerJun 9, 2020Current reportSEC
20-F/A · Annual report, amendedJun 5, 2020Annual reportSEC
20-F · Annual reportJun 1, 2020Annual reportSEC
NT 20-FJun 1, 2020Explanation requestSEC
6-K · Report of a foreign issuerMay 26, 2020Current reportSEC
6-K · Report of a foreign issuerMay 13, 2020Current reportSEC
6-K · Report of a foreign issuerApr 8, 2020Current reportSEC
6-K · Report of a foreign issuerJan 22, 2020Current reportSEC
6-K · Report of a foreign issuerJan 6, 2020Current reportSEC
6-K · Report of a foreign issuerDec 26, 2019Current reportSEC
6-K · Report of a foreign issuerDec 5, 2019Current reportSEC
6-K · Report of a foreign issuerDec 3, 2019Current reportSEC
6-K · Report of a foreign issuerOct 8, 2019Current reportSEC
6-K · Report of a foreign issuerOct 1, 2019Current reportSEC
6-K · Report of a foreign issuerSep 6, 2019Current reportSEC
10-Q · Quarterly reportJun 17, 2019Quarterly reportSEC
NT 10-Q · Late filing noticeJun 17, 2019Explanation requestSEC
8-K · Current reportMay 21, 2019FinancingSEC
10-K · Annual reportMay 3, 2019Annual reportSEC
NT 10-K · Late filing noticeApr 30, 2019Explanation requestSEC
DEF 14A · Proxy statementFeb 19, 2019Meeting noticeSEC
8-K · Current reportFeb 4, 2019FinancingSEC
8-K · Current reportDec 19, 2018Material contractSEC
10-Q · Quarterly reportDec 18, 2018Quarterly reportSEC
NT 10-Q · Late filing noticeDec 17, 2018Explanation requestSEC
8-K · Current reportNov 6, 2018FinancingSEC
8-K · Current reportSep 18, 2018Management or board changeSEC
10-Q · Quarterly reportSep 14, 2018Quarterly reportSEC
10-Q · Quarterly reportJun 19, 2018Quarterly reportSEC
NT 10-Q · Late filing noticeJun 15, 2018Explanation requestSEC
8-K/A · Current report, amendedMay 16, 2018Acquisition or disposalSEC
10-K · Annual reportMay 1, 2018Annual reportSEC
8-K · Current reportMar 12, 2018Acquisition or disposalSEC
8-K · Current reportDec 19, 2017FinancingSEC
10-Q · Quarterly reportDec 15, 2017Quarterly reportSEC
DEF 14A · Proxy statementOct 27, 2017Meeting noticeSEC
10-Q · Quarterly reportSep 15, 2017Quarterly reportSEC
NT 10-Q · Late filing noticeSep 15, 2017Explanation requestSEC
8-K · Current reportSep 12, 2017Material contractSEC
10-Q · Quarterly reportJun 13, 2017Quarterly reportSEC
10-K · Annual reportApr 28, 2017Annual reportSEC
10-Q · Quarterly reportDec 9, 2016Quarterly reportSEC
DEF 14A · Proxy statementNov 28, 2016Meeting noticeSEC
10-Q · Quarterly reportSep 12, 2016Quarterly reportSEC
10-Q · Quarterly reportJun 14, 2016Quarterly reportSEC
10-K/A · Annual report, amendedJun 7, 2016Annual reportSEC
10-K · Annual reportApr 29, 2016Annual reportSEC
8-K/A · Current report, amendedFeb 3, 2016Acquisition or disposalSEC
10-Q · Quarterly reportDec 15, 2015Quarterly reportSEC
DDec 7, 2015Other filingsSEC
DEF 14A · Proxy statementNov 25, 2015Meeting noticeSEC
8-K · Current reportNov 23, 2015Material contractSEC
8-K · Current reportNov 18, 2015Management or board changeSEC
8-K · Current reportNov 17, 2015Material contractSEC
10-Q · Quarterly reportSep 10, 2015Quarterly reportSEC
8-K · Current reportJul 30, 2015FinancingSEC
10-Q · Quarterly reportJun 17, 2015Quarterly reportSEC
10-K/A · Annual report, amendedJun 17, 2015Annual reportSEC
NT 10-Q · Late filing noticeJun 15, 2015Explanation requestSEC
10-K · Annual reportMay 15, 2015Annual reportSEC
NT 10-K · Late filing noticeMay 4, 2015Explanation requestSEC
8-K · Current reportApr 17, 2015Current reportSEC
8-K · Current reportMar 26, 2015Material contractSEC
5 · Annual statement of ownershipMar 10, 2015Insider tradeSEC
5 · Annual statement of ownershipMar 10, 2015Insider tradeSEC
3 · Initial statement of ownershipMar 10, 2015Insider tradeSEC
3 · Initial statement of ownershipMar 3, 2015Insider tradeSEC
3 · Initial statement of ownershipMar 3, 2015Insider tradeSEC
8-K · Current reportFeb 10, 2015Management or board changeSEC
10-Q · Quarterly reportDec 15, 2014Quarterly reportSEC
8-K · Current reportOct 9, 2014Meeting outcomeSEC
10-Q · Quarterly reportSep 15, 2014Quarterly reportSEC
DEFR14AAug 27, 2014Meeting noticeSEC
UPLOAD · Letter from the SECAug 25, 2014Other filingsSEC
DEFR14AAug 20, 2014Meeting noticeSEC
UPLOAD · Letter from the SECAug 15, 2014Other filingsSEC
PRE 14A · Preliminary proxy statementAug 8, 2014Meeting noticeSEC
8-K · Current reportJul 28, 2014Management or board changeSEC
10-Q · Quarterly reportJun 16, 2014Quarterly reportSEC
8-K · Current reportJun 4, 2014Meeting outcomeSEC
10-K · Annual reportMay 16, 2014Annual reportSEC
NT 10-K · Late filing noticeMay 2, 2014Explanation requestSEC
DEF 14A · Proxy statementApr 30, 2014Meeting noticeSEC
UPLOAD · Letter from the SECApr 10, 2014Other filingsSEC
CORRESP · Letter to the SECApr 9, 2014Other filingsSEC
UPLOAD · Letter from the SECApr 8, 2014Other filingsSEC
PRE 14A · Preliminary proxy statementApr 1, 2014Meeting noticeSEC
8-K · Current reportMar 18, 2014Current reportSEC
10-Q · Quarterly reportDec 16, 2013Quarterly reportSEC

This page holds 200 of 244 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from BetterLife Pharma Inc.’s releases · as of Sep 17, 2026

Common shares
651,340,512
Fully diluted
877,049,527

Fully diluted

LineSharesAs of
Common shares651,340,512Jun 22, 2026
Warrants212,909,015Sep 17, 2026
Options and RSUs12,800,000Jun 15, 2026

Warrants and options

Lot
Broker warrants · C$0.25 · expire Sep 17, 2029
Warrants · C$0.10 · expire about Jun 2029
Warrants · C$0.10 · expiry not stated
Stock options · C$0.07 · expiry not stated
Stock options · C$0.25 · expiry not stated
Stock options · expiry not stated
Stock options · expiry not stated
Stock options · expiry not stated
Stock options · C$0.29 · expiry not stated
Stock options · C$0.19 · expiry not stated
All 12 lots
Lot
Stock options · C$0.065 · expire Jun 15, 2036
Stock options · C$0.065 · expiry not stated

Share count over time

CountShares
Nov 22, 2026651,340,512

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Kalehua Capital Management LLC27.7M4.3%US$6.68MSep 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Steven Sangha
10% Security Holder of Issuer
Buy33,333,333CAD 0.06CAD 2MNov 5, 2026
Douglas Lee Drysdale
Director of Issuer
Buy51,867CAD 0.27CAD 14,004Oct 7, 2026
Ahmad Doroudian
Director of Issuer
Buy50,000CAD 0.09CAD 4,250Jun 23, 2026
Ahmad Doroudian
Director of Issuer
Buy50,000CAD 0.07CAD 3,500Jun 22, 2026
Steven Sangha
10% Security Holder of Issuer
Buy52,000CAD 0.06CAD 3,120Jun 5, 2026
Steven Sangha
10% Security Holder of Issuer
Buy229,000CAD 0.06CAD 13,740Jun 4, 2026
Steven Sangha
10% Security Holder of Issuer
Buy121,000CAD 0.06CAD 7,260Jun 1, 2026
Steven Sangha
10% Security Holder of Issuer
Buy126,000CAD 0.06CAD 7,560May 29, 2026
Steven Sangha
10% Security Holder of Issuer
Buy127,000CAD 0.06CAD 7,620May 28, 2026
Steven Sangha
10% Security Holder of Issuer
Buy327,000CAD 0.06CAD 19,620May 27, 2026
All 46 trades
TradeTradeSharesPriceValueDate
Steven Sangha
10% Security Holder of Issuer
Buy2,000CAD 0.06CAD 120May 27, 2026
Steven Sangha
10% Security Holder of Issuer
Buy15,000CAD 0.06CAD 900May 26, 2026
Steven Sangha
10% Security Holder of Issuer
Sale4,221,880CAD 0.06CAD 253KMay 25, 2026
Steven Sangha
10% Security Holder of Issuer
Buy3,993,073CAD 0.06CAD 240KMay 25, 2026
Steven Sangha
10% Security Holder of Issuer
Buy4,000CAD 0.06CAD 240May 25, 2026
Steven Sangha
10% Security Holder of Issuer
Buy77,000CAD 0.06CAD 4,620May 22, 2026
Steven Sangha
10% Security Holder of Issuer
Buy281,000CAD 0.06CAD 16,860May 7, 2026
Ralph Anthony Pullen
Director of Issuer
Sale19,000CAD 0.06CAD 1,140May 6, 2026
Ralph Anthony Pullen
Director of Issuer
Sale50,000CAD 0.06CAD 3,000May 6, 2026
Ralph Anthony Pullen
Director of Issuer
Sale111,000CAD 0.07CAD 7,215May 5, 2026
Steven Sangha
10% Security Holder of Issuer
Buy259,000CAD 0.06CAD 15,540Apr 27, 2026
Steven Sangha
10% Security Holder of Issuer
Buy126,000CAD 0.06CAD 7,560Apr 24, 2026
Ralph Anthony Pullen
Director of Issuer
Sale20,000CAD 0.07CAD 1,300Apr 21, 2026
Ralph Anthony Pullen
Director of Issuer
Sale50,000CAD 0.06CAD 3,000Apr 20, 2026
Steven Sangha
10% Security Holder of Issuer
Buy166,000CAD 0.06CAD 9,960Apr 17, 2026
Steven Sangha
10% Security Holder of Issuer
Buy216,000CAD 0.06CAD 12,960Apr 17, 2026
Steven Sangha
10% Security Holder of Issuer
Buy2,000CAD 0.06CAD 120Apr 10, 2026
Steven Sangha
10% Security Holder of Issuer
Buy96,000CAD 0.06CAD 5,760Apr 8, 2026
Steven Sangha
10% Security Holder of Issuer
Buy26,000CAD 0.06CAD 1,560Mar 31, 2026
Ahmad Doroudian
Director of Issuer
Buy60,000CAD 0.07CAD 4,200Mar 9, 2026
Steven Sangha
10% Security Holder of Issuer
Buy61,000CAD 0.07CAD 3,965Mar 9, 2026
Steven Sangha
10% Security Holder of Issuer
Buy100,000CAD 0.06CAD 6,000Feb 26, 2026
Steven Sangha
10% Security Holder of Issuer
Buy43,500CAD 0.06CAD 2,610Feb 25, 2026
Steven Sangha
10% Security Holder of Issuer
Buy50,000CAD 0.06CAD 2,750Feb 25, 2026
Steven Sangha
10% Security Holder of Issuer
Buy100,000CAD 0.06CAD 6,000Feb 6, 2026
Steven Sangha
10% Security Holder of Issuer
Buy100,000CAD 0.06CAD 5,500Feb 2, 2026
Steven Sangha
10% Security Holder of Issuer
Buy100,000CAD 0.06CAD 5,500Jan 29, 2026
Steven Sangha
10% Security Holder of Issuer
Buy200,000CAD 0.05CAD 10,000Jan 27, 2026
Steven Sangha
10% Security Holder of Issuer
Buy200,000CAD 0.05CAD 10,000Jan 23, 2026
Steven Sangha
10% Security Holder of Issuer
Buy200,000CAD 0.05CAD 10,000Jan 15, 2026
Steven Sangha
10% Security Holder of Issuer
Buy10,000CAD 0.05CAD 500Jan 9, 2026
Steven Sangha
10% Security Holder of Issuer
Buy150,000CAD 0.05CAD 7,500Jan 8, 2026
Steven Sangha
10% Security Holder of Issuer
Buy100,000CAD 0.04CAD 4,500Dec 23, 2025
Ahmad Doroudian
Director of Issuer
Buy9,000CAD 0.05CAD 450Dec 16, 2025
Ahmad Doroudian
Director of Issuer
Buy10,000CAD 0.05CAD 500Dec 16, 2025
Ahmad Doroudian
Director of Issuer
Buy12,000CAD 0.06CAD 720Nov 25, 2025

Big stakes

StakeStakeSharesDateFiling
Steven Sangha15.58%26.5MSep 14, 2026Management information circular
Ahmad Doroudian10.44%17.8MSep 14, 2026Management information circular
Ra Capital Management, L.P.9.00%55.4MSep 15, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Barbara-Jean Anne Bormann-Kennedy
Other companies: BioLineRX Ltd. (Director · Since at least Mar 18, 2026); Xeris Biopharma Holdings, Inc. (Director · Since at least Oct 5, 2021)
President, Director · Feb 5, 2015 – Feb 5, 2015 · Past
Moira Ong
Other companies: Vansen Pharma Inc (CFO/Secretary · Feb 24, 2014 – Feb 24, 2014 · Past)
Chief Financial Officer · Mar 3, 2015 – Mar 3, 2015 · Past
Ahmad DoroudianChief Executive Officer & Director · Since at least Mar 10, 2015
Bri LeesHead of Marketing · Oct 23, 2025 – Nov 4, 2026 · Past
Charles DuncanDirector · Since at least Aug 31, 2026
Doug DrysdaleExecutive Chairman · Since at least May 13, 2026
Doug DrysdaleExecutive Chairman and Director · Since May 13, 2026 · Appointed, no departure found
Henry ChowMember of the Board of Directors · Since at least Nov 5, 2026
John W. LaRoccaDirector · Since at least Jul 9, 2026
Mahan ChehrenamaChief Medical Officer · Since at least Aug 19, 2026
All 15 people
PersonSeat
Mark SwaimOfficer · Since May 11, 2020 · Appointed, no departure found
Richard B. LiptonCo-Chair · Oct 19, 2026 – Nov 5, 2026 · Past
Sheila LeitzingerHead of Clinical Operations · Since at least Oct 15, 2026
Steven SanghaDirector · Mar 31, 2025 – Nov 4, 2026 · Past
Toni RinowUntil Jan 22, 2020 · Past

Open People

Log in to ask 6ix AI your own questions about BetterLife Pharma Inc.